PR98543

PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire=KYODO JBN/ --

EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project

with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness

Innovations), to develop universal vaccines for betacoronaviruses, including

SARS-CoV-2. EpiVax will be carrying out the vaccine epitope selection portion

of the collaboration using their comprehensive in silico vaccine design toolkit

"iVAX" (

https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=2887996362&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment%2Fivax-web-based-vaccine-design&a=their+comprehensive+in+silico+vaccine+design+toolkit+%22iVAX%22

).

Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg

This program is funded under CEPI's 2021 call for proposals (

https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=1939935105&u=https%3A%2F%2Fcepi.net%2Fnews_cepi%2Fcepi-launches-funding-call-to-advance-development-of-broadly-protective-coronavirus-vaccines%2F&a=CEPI%27s+2021+call+for+proposals

) to accelerate the development of broadly protective coronavirus vaccines,

which will provide up to US$200 million for such projects. Intravacc was

awarded $4.8 million to advance their subunit vaccine candidate "Avacc 101" (

https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=1203321623&u=https%3A%2F%2Fcepi.net%2Fnews_cepi%2Fcepi-partners-with-intravacc-to-develop-an-intranasal-broadly-protective-betacoronavirus-vaccine%2F&a=Intravacc+was+awarded+%244.8+million+to+advance+their+subunit+vaccine+candidate+%22Avacc+101

), which is designed for intranasal delivery to provide protective immunity for

multiple betacoronaviruses including SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Avacc 101 uses Intravacc's Outer Membrane Vesicle (OMV) technology (

https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=1303454865&u=https%3A%2F%2Fwww.intravacc.nl%2Fplatforms%2Fouter-membrane-vesicles-platform%2F&a=Intravacc%27s+Outer+Membrane+Vesicle+(OMV)+technology

) to deliver vaccine payloads for an effective immune response.

As a subgrantee on the project, EpiVax will identify cross-reactive

beta-coronavirus T cell epitopes for broad coverage of COVID-19, MERS and SARS

Class 1 and Class 2 HLA-restricted epitopes, using the iVAX in silico vaccine

design toolkit (

https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=3280241035&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment%2Fivax-web-based-vaccine-design&a=iVAX+in+silico+vaccine+design+toolkit

). In addition to vaccine epitope selection, EpiVax will also develop multiple

designs, and will validate these in silico constructs in vivo with

HLA-transgenic mice.

According to EpiVax CEO/CSO Dr. Annie De Groot, "We sincerely appreciate the

opportunity to apply our advanced vaccine design tools to a problem of global

significance.".

About EpiVax:

EpiVax is a biotechnology company with expertise in T cell epitope prediction,

immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening

toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in

advancing the research of a global roster of companies. For more information,

visit www.epivax.com.

About Intravacc:

Intravacc is a leading global contract development and manufacturing

organization (CDMO) of innovative vaccines against infectious diseases.

Intravacc has transferred its technology related to polio vaccines, measles

vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world.

Intravacc offers a wide range of expertise to develop vaccine from concept to

Phase I/II clinical studies for academic, industry and philanthropic partners.

For more information, visit www.intravacc.nl .

Press Contact:

Katie Porter, Associate Director, Business Development & Marketing

EpiVax

kporter@epivax.com

Source: EpiVax Inc.